BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Equities researchers at Truist Securiti increased their Q4 2020 EPS estimates for BioDelivery Sciences International in a report issued on Tuesday, January 12th. Truist Securiti analyst G. Gilbert now forecasts that the specialty pharmaceutical company will earn $0.08 per share for the quarter, up from their prior estimate of $0.07. Truist Securiti also issued estimates for BioDelivery Sciences International’s FY2022 earnings at $0.61 EPS, FY2023 earnings at $0.83 EPS and FY2024 earnings at $1.04 EPS.

BDSI has been the subject of several other reports. Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating and set a $4.00 target price for the company. in a research note on Thursday, October 15th. BidaskClub cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Wednesday, December 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. BioDelivery Sciences International currently has an average rating of “Hold” and a consensus price target of $7.71.

NASDAQ BDSI opened at $4.47 on Wednesday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.80 and a current ratio of 3.16. The firm’s 50 day moving average price is $4.25 and its 200-day moving average price is $4.08. BioDelivery Sciences International has a 52-week low of $2.85 and a 52-week high of $6.19. The company has a market cap of $451.97 million, a PE ratio of 31.93 and a beta of 0.72.

BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $0.09 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.04. BioDelivery Sciences International had a net margin of 10.16% and a return on equity of 25.04%. The firm had revenue of $39.44 million for the quarter, compared to the consensus estimate of $38.87 million.

In other BioDelivery Sciences International news, insider James Vollins sold 9,505 shares of the firm’s stock in a transaction dated Wednesday, December 16th. The shares were sold at an average price of $4.48, for a total transaction of $42,582.40. Following the completion of the transaction, the insider now directly owns 20,320 shares in the company, valued at approximately $91,033.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeffrey Allen Bailey sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, December 15th. The stock was sold at an average price of $4.35, for a total transaction of $43,500.00. Following the sale, the chief executive officer now directly owns 35,567 shares in the company, valued at $154,716.45. The disclosure for this sale can be found here. Insiders have sold a total of 39,825 shares of company stock valued at $176,710 over the last 90 days. 8.57% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in BDSI. PNC Financial Services Group Inc. boosted its stake in shares of BioDelivery Sciences International by 42.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 32,800 shares of the specialty pharmaceutical company’s stock worth $144,000 after purchasing an additional 9,800 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of BioDelivery Sciences International by 6.8% in the second quarter. California Public Employees Retirement System now owns 203,601 shares of the specialty pharmaceutical company’s stock worth $888,000 after acquiring an additional 12,968 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of BioDelivery Sciences International by 5.2% in the second quarter. Bank of New York Mellon Corp now owns 346,205 shares of the specialty pharmaceutical company’s stock worth $1,510,000 after acquiring an additional 17,052 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of BioDelivery Sciences International by 6.2% in the second quarter. Goldman Sachs Group Inc. now owns 1,031,707 shares of the specialty pharmaceutical company’s stock worth $4,498,000 after acquiring an additional 60,087 shares during the last quarter. Finally, American International Group Inc. boosted its position in shares of BioDelivery Sciences International by 9.9% in the second quarter. American International Group Inc. now owns 54,320 shares of the specialty pharmaceutical company’s stock worth $237,000 after acquiring an additional 4,876 shares during the last quarter. 67.40% of the stock is currently owned by institutional investors.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies.

Further Reading: Special Dividends

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.